A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits

Prostate

Volumn 69, Issue 8, 2009, Pages 895-907

  Montorsi, Francesco ^a   Alcaraz, Antonio ^b   Desgrandchamps, François ^c   Hammerer, Peter ^d   Schröder, Fritz ^e   Castro, Ramiro ^f  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c SAINT LOUIS HOSPITAL   (France)

^d Academic Hospital   (Germany)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f Medical Affairs   (Spain)

Author keywords

Benign prostatic enlargement; Benign prostatic hyperplasia; Dutasteride; Finasteride; Prostate cancer

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; GONADORELIN AGONIST; KETOCONAZOLE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; AZASTEROID; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE; SULFONAMIDE; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CASTRATION; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; DRUG EFFICACY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATECTOMY; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT PLANNING; AGED; AGING; BLOOD; DRUG ANTAGONISM; GROWTH, DEVELOPMENT AND AGING; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REVIEW; URINARY TRACT INFECTION;

AGED; AGING; AZASTEROIDS; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SULFONAMIDES; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE; URINARY TRACT INFECTIONS;

EID: 65549152762     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20939     Document Type: Article

References (75)

1. Carson C III, , Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003;61:2-7. (Pubitemid 36349123)
2. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990;126:1165-1172. (Pubitemid 20079537)
3. Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 1999;84: 3463-3468. (Pubitemid 30645192)
4. Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: Role of 5alpha-reductase. Endocrinology 1999;140:4509-4515.
5. Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms - A comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54:273-279.
6. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, OBrien SP, Rittmaster RS. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231-239. (Pubitemid 40571057)
7. Titus MA, Gregory CW, Ford OH III, , Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-redutase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365-4371. (Pubitemid 40825625)
8. Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, Rittmaster RS, Too CK. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008;179:147-151. (Pubitemid 350216746)
9. Titus M, Li Y, Kawinski E, Kozyreva O, Mohler JL. Biochemical and pharmacoligical evidence for a third isozyme of steroid 5a-reductase in prostate cancer. J Urol 2007;177(4Suppl): Abstract # 268.
10. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, Nakagawa H. Novel 5 alpha-steroid reductase (SRD5A3, type 3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99:81-86. (Pubitemid 350239034)
11. Carlin JR, Höglund P, Eriksson LO, Christofalo P, Gregoire SL, Taylor AM, Anderson KE. Disposition and pharmacokinetics of [14C] finasteride after oral administration in humans. Drug Metab Dispos 1992;20:148-155.
12. Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)- 3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 1991;16:15-21.
13. Tian G, Mook RA Jr., Moss ML, Frye SV. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: Towards perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 1995;34: 13453-13459.
14. Evans HC, Goa KL. Dutasteride. Drugs Aging 2003;20:906-916.
15. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179-2184. (Pubitemid 38619850)
16. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-508.
17. Span PN, Voller MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 1999;161:332-337. (Pubitemid 29422357)
18. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172:915-919. (Pubitemid 39096422)
19. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentration in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007;10:149-154. (Pubitemid 46881666)
20. Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, Steinhoff G, Fleshner N, Bostwick D, Thomas L, Rittmaster R. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study. Prostate 2006;66:1674-1685. (Pubitemid 44646358)
21. Madersbacher S, Alivizatos G, Nordling J, Rioja Sanz C, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPHguidelines). Eur Urol 2004;46:547-554. (Pubitemid 39345720)
22. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk. Eur Urol 2001;39:390-399.
23. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;5453:581-589. (Pubitemid 29136206)
24. Bartsch G, Fitzpatrick JM, Schalken JA, Isaacs J, Nordling J, Roehrborn CG. Consensus statement: The role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 2004;93(Suppl1):27-29.
25. McConnell JD, Bruskewitz R, Walsh P, Andriole GL, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 1998;338:557-563.
26. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-441. (Pubitemid 35292169)
27. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TLJ, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-494. (Pubitemid 39200858)
28. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398. (Pubitemid 37542987)
29. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-539. (Pubitemid 26272307)
30. Kirby R, Robertson C, Turkes A, Griffiths K, Denis LS, Boyle P, Altwein J, Schröder F. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. Prostate 1999;40:105-114. (Pubitemid 29304701)
31. Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, Major-Walker K, Morrill BB. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: The CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007;28:770-779.
32. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B, Montorsi F. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-621.
33. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, Rittmaster RI. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314-1317.
34. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224. (Pubitemid 36859473)
35. Andriole G, Roehrborn CG, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004;64: 537-541. (Pubitemid 39200753)
36. Kaplan SA, Ghafar MA, Volpe MA, Lam JS, Fromer D, Te AE. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: Preliminary study. Urology 2002;60:464-468.
37. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006;175:1657-1662.
38. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5a-reductase inhibitors: A review and clinical recommendations. J Urol 2006;176:868-874.
39. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-1133. (Pubitemid 44288787)
40. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA Jr. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177:1749-1752. (Pubitemid 46560657)
41. Mitterberger M, Pinggera G, Horninger W, Strasser H, Halpern E, Pallwein L, Gradl J, Bartsch G, Frauscher F. Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection. Eur Urol 2008;53:112-117. (Pubitemid 350166703)
42. Ives EP, Gomella LG, Halpern EJ. Effect of dutasteride therapy on Doppler US evaluation of prostate: Preliminary results. Radiology 2005;237:197-201.
43. Ickzowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole G, Bostwick DG. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005;65:76-82. (Pubitemid 40169609)
44. Andriole G, Lieber M, Smith J, Soloway M, Schröder F, Kadmon D, Dekernion J, Rajfer J, Boake R, Carwford D, Ramsey E, Perreault J, Trachtenberg J, Fradet Y, Block N, Middleton R, Ng J, Ferguson D, Gormley G. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995;45:491-497.
45. Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients. Oncologist 2001;6:177-182.
46. Tucker S, Roundy JN, Leibowitz R. Primary triple androgen blockade (TAB) followed by finasteride maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL). 2005 ASCO Prostate Cancer Symposium, abstract106. Available from:http://www.asco.org/ portal/ site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD & vmview=abst-detail- view&confID=37&abstractID=20271 [accessed 26th June 2008].
47. Picus J, Halabi S, Small E, Hussain A, Philips G, Kaplan E, Vogelzang N.Longterm efficacy of peripheral and rogen blockade on prostate cancer: CALGB9782. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I;24: 4573.
48. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MC, Sweeney M, Grossman EB. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-126.
49. Sartor AO, Nakabayashi M, Taplin ME, Ross R, Kantoff P, Balk S, Oh K. Activity of dutasteride plus ketoconazole in hormone-refractory prostate cancer (HRPC) after progression on ketoconazole alone. 2007 ASCO Prostate Cancer Symposium, abstract 257. Available from: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst-detail- view&confID=46&abstractID=20212 [accessed 12th November 2008].
50. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology 2006;68:116-120. (Pubitemid 44037733)
51. Cussenot O, Azzouzi AR, Nicolaiew N, Mangin P, Cormier L, Fournier G, Valeri A, Cancel-Tassin G. Low-activity, V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: An explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 2007;52: 1082-1087.
52. Soderstrom T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F, Rane A. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002;12:307-312. (Pubitemid 34620658)
53. Shibata A, Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, Henderson S, Yemoto CE, Peehl DM. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate 2002;52:269-278.
54. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, Gann PH. Detection bias due to the effect of finasteride on prostate volume: Amodeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99: 1366-1374.
55. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr., Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-1383.
56. Redman MW, Tangen CM, Goodman PJ, Lucia SM, Coltman CA Jr., Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modelling approach. Cancer Prev Res 2008;1:174-181.
57. Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lipman SM, Coltman CA Jr., Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 2007;178: 107-109. (Pubitemid 46908725)
58. Marberger M, Adolfsson J, Borkowski A, Fitzpatrick J, Kirk D, Prezioso D, Rabaca C, Solsona E, Teillac P. The clinical implications of the Prostate Cancer Prevention Trial. BJU Int 2003;92: 667-671. (Pubitemid 37479306)
59. Yan Y, Carvalhal GF, Catalona WJ, Young D. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000;88:1122-1130. (Pubitemid 30127674)
60. Harlan SR, Cooperberg MR, Elkin EP, Lubeck DP, Meng MV, Mehta SS, Carroll PR. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 2003;170: 1804-1807.
61. Lucia MS, Darke AK, Goodman PJ, LaRosa F, Parnes HL, Ford LG, Coltman CA Jr,, Thompson IM. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: Implications for prostate cancer detection and chemoprevention. Cancer Prev Res 2008;1:167-173.
62. Heidenreich A, Aus G, Abbou CC, Bolla M, Joniau S, Matveev V, Schmid H-P, Zattoni F. EAU guidelines on prostate cancer 2007. Available from: http://www.uroweb.org/fileadmin/user- upload/Guidelines/07-Prostate-Cancer-2007. pdf [accessed 26th June 2007].
63. Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006;175:505-509. (Pubitemid 43067339)
64. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 1995;45:282-290.
65. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5a-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004;58:130-144. (Pubitemid 38160900)
66. Sutton MT, Yingling M, Vyas A, Atiemo H, Borkowski A, Jacobs SC, Kyprianou N. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate 2006;66:1194-1202. (Pubitemid 44175341)
67. McCrohan A, Morrissey C, OKeane C, Mulligan N, Watson C, Smith J, Fitzpatrick JM, Watson RWG. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer 2006; 106:2743-2752. (Pubitemid 43911845)
68. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006;12:4072-4079. (Pubitemid 44078095)
69. Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R. Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007;28:763-769.
70. Gades NM, Jacobson DJ, Girman CJ, Roberts RO, Lieber MM, Jacobsen SJ. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int 2005;95:549-553. (Pubitemid 40311471)
71. Schulman C, Lunenfeld B. The ageing male. World J Urol 2002;20:4-10.
72. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho S-M, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer 2004;101:2371-2490. (Pubitemid 39505434)
73. Andriole G, Brawley O, Tammela TL, Rittmaster R. Chemoprevention of prostate cancer: Baseline characteristics of men in the REDUCE trial. Eur Urol Suppl 2005;4:184.
74. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005;118:850-857.
75. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. The cost of prostate cancer chemoprevention: A decision analysis model. Cancer Epidemiol Biomarkers Prev 2006;15:1485-1489.